Literature DB >> 11005325

Antireflux surgery, highly selective vagotomy and duodenal switch procedure: post-operative evaluation in patients with complicated and non-complicated Barrett's esophagus.

I Braghetto1, A Csendes, P Burdiles, O Korn.   

Abstract

Antireflux surgery, highly selective vagotomy (HSV) and Roux-en-Y duodenojejunostomy have been suggested for control of pathophysiological factors involved in patients with Barrett's esophagus (BE). The aim of this study was to evaluate prospectively the results of this technique in patients with complicated (n = 21) and noncomplicated (n=45) BE. Complete evaluation of esophageal function, endoscopic histologic and clinical control was carried out before and 2 years after surgery. Post-operative results show recurrence of ulcer in patients with complicated BE, but no recurrence in patients with non-complicated BE. Preoperative esophageal ulcer and stricture were present in 85.3% and 14.3%, respectively, of patients with complicated BE. In this group, recurrence of these complications was 38.1% and 9.5% respectively. The technique offers excellent results in patients with non-complicated BE. However, in patients with complicated BE, the recurrence rate is higher, mainly because of the persistence of acid reflux into the esophagus.

Entities:  

Mesh:

Year:  2000        PMID: 11005325     DOI: 10.1046/j.1442-2050.2000.00066.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  2 in total

1.  Barrett's esophagus without esophageal stricture does not increase the rate of failure of Nissen fundoplication.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Andres Serrano; Gloria Torres
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

2.  Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience.

Authors:  S E Attwood; L Lundell; J G Hatlebakk; S Eklund; O Junghard; J-P Galmiche; C Ell; R Fiocca; T Lind
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.